© Bayer AG

Bayer AG has joined forces with young Danish biotech Gubra ApS in a research collaboration and license agreement for the development of peptide therapeutics to treat cardiorenal diseases.

© Kelly Davidson Photography via Broad Institute

The Novo Nordisk Foundation is investing US$47.5m into a research collaboration with the Broad Institute of MIT and Harvard, intending to dive into the disease mechanisms of diabetes and obesity.

Gerd Altmann/pixabay.com

UK-based DNA synthesis specialist Touchlight Ltd has extended a funding round to  a current aggregate total of US $125m.

© tomwieden / Pixabay

Royal DSM is backing Meatable, the cultivated meat start-up, in order to develop growth media for cultivated meat.

What_are_the_Ingredients_of_an_mRNA_Vaccine.png

mRNA technology has revolutionized vaccine development. What are the chemical components that make up a typical mRNA vaccine and what are their functions? What analytical testing can be done to support this?

image001.jpg

CAD is a universal detector able to detect all non-volatile, and many semi-volatile analytes. This uniform response enables accurate quantitation of most excipients in a vaccine formulation.  

Laboratorium für Klinische Forschung (LKF): Co-Founder and CEO Bärbel Wilke, Picture: LKF

This year LKF Central Laboratory, which specialises in international clinical trials, celebrates its 30th anniversary. Although size and services have developed significantly since the beginning, LKF´s corporate philosophy is still the same. With its dedicated team, LKF supports clinical trials with an individual and study-oriented, flexible approach with consistent high-quality laboratory standards.

Eppendorf_AG_press_image_epT.I.P.S._Box_2.0.jpg

The new box is now called Box 2.0. The new design is a consistent, modern further development of the original product outfit.

At the beginning of September, Stephan Goldenbaum became the new CEO of Estonian Solis BioDyne OÜ. CEO Priit Karjus stepped down to continue the Supervisory Board.

EnteroBiotix closes an oversubscribed Series A financing with US$21.5m. The biopharma company will use the proceeds to advance its microbiome drug pipeline.